Jasper Therapeutics, Inc.
JSPR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001788028
No open-market purchases or sales by Jasper Therapeutics, Inc. insiders were filed in the last 90 days; 45 institutions reported holding it in 13F filings for Q2 2026, worth $5.05M in total; no superinvestor holds it.
Other share classesJSPRW
13F holders, Q3 2022
Institutional positions in Jasper Therapeutics, Inc. as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 23
- 0 vs. Q2 2022
- Shares held
- 20.3M
- +412.4K (+2.1%) vs. Q2 2022
- Total value
- $15.7M
- −$21.7M (−58.0%) vs. Q2 2022
- New holders
- 5
- 7 more added
- Sold out
- 5
- 3 more reduced
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting JSPR on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 45 | $5.05M |
| Q1 2026 | 58 | $13.9M |
| Q4 2025 | 55 | $35.2M |
| Q3 2025 | 60 | $47.8M |
| Q2 2025 | 65 | $69.5M |
| Q1 2025 | 69 | $56.1M |
| Q4 2024 | 88 | $334.5M |
| Q3 2024 | 81 | $274.8M |
| Q2 2024 | 69 | $329.8M |
| Q1 2024 | 61 | $380.2M |
| Q4 2023 | 42 | $61.2M |
| Q3 2023 | 41 | $63.7M |
| Q2 2023 | 46 | $120.0M |
| Q1 2023 | 45 | $168.8M |
| Q4 2022 | 23 | $9.57M |
| Q3 2022 | 23 | $15.7M |
| Q2 2022 | 23 | $37.5M |
| Q1 2022 | 24 | $69.6M |
| Q4 2021 | 25 | $160.7M |
| Q3 2021 | 9 | $101.4M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Jasper Therapeutics, Inc.; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Qiming U.S. Ventures Management, LLC | 5,852,982 | $4.62M | 6.71% | 00.0% | Unchanged |
| Abingworth LLP | 5,628,558 | $4.44M | 1.52% | 00.0% | Unchanged |
| Citadel Advisors LLC | 3,102,016 | $2.45M | 0.00% | +129,013+4.3% | Added |
| Velan Capital Investment Management LP | 3,219,036 | $2.24M | 2.62% | 00.0% | Unchanged |
| Kingdon Capital Management, L.L.C. | 540,000 | $426.0K | 0.13% | 00.0% | Unchanged |
| Vanguard Group Inc | 530,120 | $418.0K | 0.00% | +49,559+10.3% | Added |
| Sectoral Asset Management Inc | 400,000 | $316.0K | 0.06% | −315,360−44.1% | Reduced |
| Fernwood Investment Management, LLC | 297,080 | $234.0K | 0.10% | +297,080 | New |
| BlackRock Inc. | 213,027 | $168.0K | 0.00% | −5,047−2.3% | Reduced |
| UBS Group AG | 188,026 | $148.0K | 0.00% | +182,487+3,294.6% | Added |
| Geode Capital Management, LLC | 127,734 | $100.0K | 0.00% | 00.0% | Unchanged |
| Forefront Analytics, LLC | 119,800 | $94.0K | 0.05% | +85,175+246.0% | Added |
| State Street Corp | 32,884 | $26.0K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 28,600 | $23.0K | 0.00% | +28,600 | New |
| Northern Trust Corp | 21,460 | $17.0K | 0.00% | 00.0% | Unchanged |
| Virtu Financial LLC | 14,717 | $12.0K | 0.00% | +14,717 | New |
| Tower Research Capital LLC (TRC) | 13,682 | $11.0K | 0.00% | +9,071+196.7% | Added |
| Morgan Stanley | 3,125 | $2.00K | 0.00% | +125+4.2% | Added |
| Royal Bank of Canada | 2,555 | $2.00K | 0.00% | 00.0% | Unchanged |
| Group One Trading, L.P. | 300 | $0 | 0.00% | −100−25.0% | Reduced |
| Wells Fargo & Company | 267 | $0 | 0.00% | +9+3.5% | Added |
| Ionic Capital Management LLC | 100 | $0 | 0.00% | +100 | New |
| Simplex Trading, LLC | 1,003 | $0 | 0.00% | +1,003 | New |
| BIT Capital GmbH | 0 | $0 | 0.00% | −30,000−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −16,832−100.0% | Sold out |
| Goldman Sachs Group Inc | 0 | $0 | 0.00% | −10,269−100.0% | Sold out |
| Penserra Capital Management LLC | 0 | $0 | 0.00% | −6,706−100.0% | Sold out |
| Citigroup Inc | 0 | $0 | 0.00% | −195−100.0% | Sold out |